Although there was no formal statistically significant interaction for the association between GLP-1 RA use and the primary outcome in patients with vs. without obesity (P-value for interaction: 0.07), in the stratum of patients with a BMI ≥30 kg/m2, use of GLP-1 RA was associated with a statistically significant lower risk of CV death or HF hospitalization, as well as HF hospitalization, CV and all-cause death, and MACE regardless of EF. Here, GLP1R is linked to hydrops fetalis.